Nexium (Esomeprazole Magnesium Trihydrate)

Nexium, a proton pump inhibitor, is employed in the management of several acid‑related gastrointestinal conditions.

• Gastroesophageal reflux disease (GERD): alleviates heartburn and esophageal irritation by maintaining higher gastric pH.
• Erosive esophagitis: promotes healing of acid‑induced esophageal lesions.
• NSAID‑induced gastric ulcer: protects gastric mucosa and facilitates ulcer healing.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion in this rare endocrine disorder.
• Helicobacter pylori eradication (as part of combination therapy): enhances the effectiveness of antibiotic regimens by reducing gastric acidity.

• Esomeprazole magnesium trihydrate binds covalently to the cysteine residues of the gastric H+/K+ ATPase (proton pump) located on the secretory surface of parietal cells, leading to irreversible inhibition of the enzyme and a sustained reduction in gastric acid secretion.

Adverse reactions to Nexium may vary in frequency and severity.

Common Side Effects

• Headache: mild to moderate pain often reported during early therapy.
• Diarrhea: loose stools occurring in a subset of patients.
• Abdominal pain: discomfort or cramping in the stomach region.
• Nausea: feeling of unease or urge to vomit.
• Flatulence: increased intestinal gas.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Clostridioides difficile infection: severe colitis associated with altered gut flora.
• Severe allergic reactions (anaphylaxis): rapid onset of rash, swelling, and breathing difficulty.
• Hypomagnesemia: low magnesium levels with prolonged use.
• Stevens‑Johnson syndrome: rare, life‑threatening skin reaction.

Before initiating Nexium, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Assess renal function: dose adjustment may be required in severe renal impairment.
• Monitor for osteoporosis: long‑term use may affect bone mineral density.
• Avoid in patients with known hypersensitivity to esomeprazole or other PPIs.
• Use with caution in hepatic impairment: consider dose reduction.
• Store at ambient temperature: keep in the original pack, protect from moisture and light.

Nexium can affect the pharmacokinetics of several co‑administered drugs; interaction severity varies.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect; avoid concurrent use.
• Atazanavir: decreased absorption of atazanavir; avoid.

Moderate Interactions (Monitor Closely)

• Warfarin: may increase INR; monitor coagulation parameters.
• Digoxin: increased serum levels; monitor for toxicity.
• Methotrexate: reduced renal clearance; monitor levels.